ArticleDoklady. Biochemistry and biophysics2021
Osteosarcoma Cell Growth Inhibition by Isoxanthanol-Nanoparticles through Histone H3 Lysine 27 Trimethylation Downregulation and AMPK Activation.
Article in Doklady. Biochemistry and biophysics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Total Synthesis and Anticancer Study of (+)-Verticillin A.Journal of the American Chemical Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study was aimed to investigate the effect of isoxanthanol-nanoparticles (IXNP) on proliferation of osteosarcoma cells and evaluate the underlying mechanism. In MG-63 and U2-OS cells proliferative potential was reduced significantly (p < 0.05) in dose-dependent manner by IXNP treatment. The IXNP treatment at 15 mg/mL suppressed MG-63 cell viability to 39% and that U2-OS cells to 43% at 48 h. Treatment with IXNP led to a prominent up-regulation of caspases-3 and -9 cleavage compared to untreated cells. Moreover, PARP and Bax levels in the cells showed a remarkable increase on IXNP-treatment in comparison to the control cells. Phosphorylation of AMPKα, expression of p21 and replication of mtDNA was also promoted in MG-63 and U2-OS cells on treatment with IXNP. In MG-63 and U2-OS cells, IXNP-treatment elevated expression of PGC-1α and TFAM while as EED, EZH2, and SUZ12 expression was down-regulated. Thus, IXNP suppress proliferation of osteosarcoma cells through activates AMPK activation and elevation of Histone H3 lysine 27 trimethylation. Therefore, IXNP has therapeutic potential to be developed for treatment of osteosarcoma.
Indexed as
Identifiers
34697742What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.